Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
In the latest session, Cogent Biosciences Inc (NASDAQ: COGT) closed at $8.10 up 0.87% from its previous closing price of $8.03. In other words, the price has increased by $0.87 from its previous closing price. On the day, 0.77 million shares were traded.
Ratios:
For a deeper understanding of Cogent Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.44 and its Current Ratio is at 6.44. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.05.
On February 26, 2024, Robert W. Baird Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $14 to $8.
On February 08, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $11.Citigroup initiated its Buy rating on February 08, 2024, with a $11 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 14 ’25 when Pinnow Cole bought 43,750 shares for $7.60 per share. The transaction valued at 332,412 led to the insider holds 45,848 shares of the business.
Stock Price History:
Over the past 52 weeks, COGT has reached a high of $12.61, while it has fallen to a 52-week low of $5.73. The 50-Day Moving Average of the stock is -3.65%, while the 200-Day Moving Average is calculated to be -12.65%.
Shares Statistics:
A total of 110.46M shares are outstanding, with a floating share count of 91.91M. Insiders hold about 16.79% of the company’s shares, while institutions hold 94.55% stake in the company.
Earnings Estimates
The stock of Cogent Biosciences Inc (COGT) is currently in the spotlight, with 9.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.64, with high estimates of -$0.57 and low estimates of -$0.7.
Analysts are recommending an EPS of between -$1.99 and -$2.53 for the fiscal current year, implying an average EPS of -$2.4. EPS for the following year is -$2.3, with 9.0 analysts recommending between -$1.48 and -$2.69.
